The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
NSABP FB-6: Phase II trial of weekly paclitaxel (WP) and pazopanib following doxorubicin and cyclophosphamide (AC) as neoadjuvant therapy for HER2-negative locally advanced breast cancer (LABC).
Antoinette R. Tan
Research Funding - GlaxoSmithKline
Marc E. Buyse
Employment or Leadership Position - IDDI, Belgium
Priya Rastogi
No relevant relationships to disclose
Samuel A. Jacobs
No relevant relationships to disclose
Andre Robidoux
Honoraria - GlaxoSmithKline
Research Funding - GlaxoSmithKline
Patrick J. Flynn
No relevant relationships to disclose
Michael P. Thirlwell
No relevant relationships to disclose
Louis Fehrenbacher
No relevant relationships to disclose
Philip J. Stella
No relevant relationships to disclose
Rakesh Goel
No relevant relationships to disclose
Thomas B. Julian
No relevant relationships to disclose
Louise Provencher
Honoraria - GlaxoSmithKline
Research Funding - GlaxoSmithKline
Martin Joseph Bury
No relevant relationships to disclose
Soonmyung Paik
No relevant relationships to disclose
Charles E. Geyer
No relevant relationships to disclose
Sandra M. Swain
Consultant or Advisory Role - Genentech (U); Nektar (U); Novartis (U); Roche (U); Sanofi (U)
Research Funding - Bristol-Myers Squibb; Novartis; Pfizer; Roche/Genentech; Sanofi
Other Remuneration - Sanofi
Eleftherios P Mamounas
No relevant relationships to disclose
Norman Wolmark
Consultant or Advisory Role - GlaxoSmithKline (U)